The capacity of interleukin 12 (IL-12) to potentiate drugs in the treatment of murine toxoplasmosis was examined. IL-12 (100 ng/injection), atovaquone (10 mg/kg of body weight/day), or clindamycin (5 mg/kg/day) administered alone caused delayed time to death or minimal survival rates. In contrast, significant survival rates resulted when the same dose of IL-12 was used in combination with the same doses of atovaquone (P ‫؍‬ 0.01) or clindamycin (P ‫؍‬ 0.001). Infected mice treated with IL-12 plus drug produced significantly higher levels of gamma interferon than controls. Although IL-12 was effective only when administered before infection, these results suggest that this cytokine may be a useful adjunct in the therapy of human toxoplasmosis in situations when cysts reactivate and tachyzoites start multiplying in immunocompromised patients.
The current therapy of choice for human toxoplasmosis is the synergistic combination of pyrimethamine plus a sulfonamide or pyrimethamine plus clindamycin (6, 13) . This combination is effective in the treatment of immunocompetent patients but may fail in the treatment of immunodeficient individuals (16, 17) . In addition, the use of sulfonamides in immunocompromised patients, particularly AIDS patients, is frequently associated with side effects that may warrant discontinuation of the drug (16, 17) . Previous observations from our laboratory revealed that gamma interferon (IFN-␥) enhanced the anti-Toxoplasma gondii activities of pyrimethamine (11) and azithromycin (4) . Because of recent reports demonstrating a critical role for interleukin 12 (IL-12) in infectious diseases (15) and in resistance to T. gondii (8, 10, 12) , it was considered of interest to examine whether this cytokine would potentiate the activities of anti-T. gondii drugs in a murine model of acute toxoplasmosis. The drugs chosen were atovaquone and clindamycin; atovaquone is active in murine models of toxoplasmosis (2) and is being evaluated for treatment of human toxoplasmosis, and clindamycin is commonly used as an alternative to sulfonamides in the treatment of human toxoplasmosis (16) .
Protective effect of IL-12 in combination with atovaquone or clindamycin. BALB/c female mice (Simonsen Laboratories, Gilroy, Calif.), weighing 20 g at the beginning of the experiments, were infected orally with 10 cysts of the C56 strain of T. gondii (5) . A previously determined optimal concentration of 100 ng of IL-12 (Genetics Institute, Cambridge, Mass.) was administered intraperitoneally either before infection (at 24 h and at 6 h, followed by a daily injection for 12 days beginning 24 h after infection) or after infection (one daily injection for 12 days beginning 24 h after infection). The desired concentration of IL-12 was prepared in RPMI 1640 tissue culture medium (Sigma Chemical Co., St. Louis, Mo.). Two experiments with 5 or 10 mg of atovaquone (lot 8810001-158; Burroughs Wellcome, Research Triangle Park, N.C.) per kg of body weight per day were conducted. With clindamycin (hydrochloride salt, lot 627; The Upjohn Co., Kalamazoo, Mich.), there were three experiments, with doses from 5 to 25 mg/kg/ day. The doses of atovaquone and of clindamycin were suboptimal and were selected to better reveal an effect of combination therapy with IL-12. Atovaquone and clindamycin were administered orally, by gavage, as a single daily dose, beginning 3 days after infection and continuing for 10 days. The purpose of the 3-day period between infection and the initiation of treatment was to allow colonization of the intestine by T. gondii tachyzoites. Atovaquone was dissolved in a small volume of dimethyl sulfoxide, and the working concentration was prepared in 0.25% carboxymethyl cellulose; clindamycin was dissolved in sterile phosphate-buffered saline. The doses of IL-12, atovaquone, and clindamycin used in the present work were chosen based on our previous experience with these drugs (2, 3, 10) .
Treatment with IL-12 alone or in combination with atovaquone or clindamycin administered after infection did not result in significant survival rates or prolongation of time to death under the conditions employed (data not shown). Significant survival rates did result, however, when IL-12 was given before infection and was continued with atovaquone or clindamycin. Fig. 1 depicts the results obtained when IL-12 was given before infection and then continued with 10 mg of atovaquone (Fig. 1A) or with 5 mg of clindamycin (Fig. 1B) per kg per day. Treatment with atovaquone alone resulted in prolongation of time to death and 40% survival, whereas treatment with IL-12 alone resulted in prolongation of time to death but 0% survival. Ninety percent of the mice treated with the same doses of atovaquone and IL-12 in combination survived ( Fig.  1A ; P ϭ 0.01, Mann-Whitney U test). Treatment with clindamycin alone resulted in 10% survival, whereas treatment with clindamycin in combination with IL-12 resulted in 100% survival ( Fig. 1B ; P Ͻ 0.001, Mann-Whitney U test). These results indicate that the capacity of atovaquone or clindamycin to protect mice against death due to acute toxoplasmosis was significantly increased when these drugs were combined with IL-12. The combinations did not prevent colonization of tissues by T. gondii, however; cysts of the parasite were present in the brains of the surviving mice.
Cytokine production. IFN-␥ is the major mediator of resistance to T. gondii (14) , and its production by T cells and NK cells is stimulated by IL-12 (15) . To understand the mechanism whereby IL-12 enhanced drug activity, we stimulated splenocytes from the experimental mice with concanavalin A (ConA) or parasite antigen and measured proliferative responses and the production of IFN-␥, IL-2, and IL-4. IFN-␥, IL-2, and IL-4 levels were assayed in 48-h spleen cell culture supernatants with a two-site capture enzyme immunoassay as previously described (1, 10) .
The supernatants of splenocyte cultures from infected mice were examined for IL-2 and IL-4 following stimulation with toxoplasma lysate antigen (TLA) by using pooled samples from mice infected for 10 days. Treatment with IL-12 plus clindamycin resulted in significant production of IL-4 (350 Ϯ 11 pg/ml) compared to baseline levels (below 19 pg/ml). IL-2 was not detected (Ͻ78 pg/ml). The levels of IFN-␥ produced by the splenocytes from infected and uninfected mice following stimulation with TLA or ConA are shown in Fig. 2 . Treatment with IL-12, but not with clindamycin, resulted in increased production of IFN-␥ by splenocytes of uninfected mice which had been stimulated with TLA or ConA or left unstimulated ( Fig. 2A) . Treatment with clindamycin also did not affect the capacity of IL-12 to enhance production of IFN-␥ by splenocytes of uninfected mice stimulated with TLA or ConA. A similar pattern of response was observed with mice treated with atovaquone. Increased production of IFN-␥ was noted in splenocytes of infected mice stimulated with TLA or ConA (Fig. 2B) . This increase was inhibited by treatment with clindamycin. Treatment with IL-12 alone resulted in enhanced production of TLA-specific IFN-␥. A marked increase in background levels of IFN-␥ and levels of TLA-specific IFN-␥ occurred in mice treated with IL-12 plus clindamycin. Thus, although treatment with clindamycin alone inhibited the production of IFN-␥ following stimulation with TLA, this ef- fect was abolished when clindamycin was used in combination with IL-12. These data correlate the protective effects of IL-12 with increased levels of TLA-specific IFN-␥. Moreover, the remarkable levels of IFN-␥ produced by splenocytes from mice treated with IL-12 plus clindamycin correlate with the enhanced survival of these mice. These data also suggest that the ability of IL-12 to direct the development of T cells which secrete IFN-␥ in an antigen-specific manner (9) or directly stimulate T-cell and NK cell production of IFN-␥ is involved in the enhanced resistance observed in mice treated with drug plus IL-12. Interestingly, drug treatment inhibits the normal immune response to T. gondii, as shown by the lack of T-cell responses by splenocytes from infected mice treated with clindamycin. Infection resulted in suppression of the proliferation of lymphocytes in response to ConA, as previously described (7) . The combination of clindamycin plus IL-12, however, resulted in a higher stimulation index for splenocytes treated with TLA than for sham-treated lymphocytes or for lymphocytes treated with IL-12 or clindamycin alone (data not shown).
The above results indicate that IL-12 is able to potentiate the activity of drugs used for treatment of toxoplasmosis. Doses of atovaquone or clindamycin that caused only marginal or no survival of mice acutely infected with T. gondii became highly protective when used in combination with a dose of IL-12 that was also not protective when used alone. Although significant protection was noted only when IL-12 was administered before the infection, the above results suggest that further studies with this and other cytokines as adjunct drugs in the treatment of humans toxoplasmosis are warranted.
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